These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 34017167)

  • 1. Multiple Sclerosis Biomarker Discoveries by Proteomics and Metabolomics Approaches.
    Jafari A; Babajani A; Rezaei-Tavirani M
    Biomark Insights; 2021; 16():11772719211013352. PubMed ID: 34017167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics in Multiple Sclerosis: The Perspective of the Clinician.
    Sandi D; Kokas Z; Biernacki T; Bencsik K; Klivényi P; Vécsei L
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integration of metabolomics and proteomics in multiple sclerosis: From biomarkers discovery to personalized medicine.
    Del Boccio P; Rossi C; di Ioia M; Cicalini I; Sacchetta P; Pieragostino D
    Proteomics Clin Appl; 2016 Apr; 10(4):470-84. PubMed ID: 27061322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients.
    Singh V; Tripathi A; Dutta R
    Proteomics; 2019 Aug; 19(16):e1800335. PubMed ID: 31119864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic, proteomic, and systems biology approaches in biomarker discovery for multiple sclerosis.
    Chase Huizar C; Raphael I; Forsthuber TG
    Cell Immunol; 2020 Dec; 358():104219. PubMed ID: 33039896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolomics in multiple sclerosis.
    Bhargava P; Calabresi PA
    Mult Scler; 2016 Apr; 22(4):451-60. PubMed ID: 26754801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current and Future Biomarkers in Multiple Sclerosis.
    Yang J; Hamade M; Wu Q; Wang Q; Axtell R; Giri S; Mao-Draayer Y
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular Vesicles as Pro- and Anti-inflammatory Mediators, Biomarkers and Potential Therapeutic Agents in Multiple Sclerosis.
    Manu MS; Hohjoh H; Yamamura T
    Aging Dis; 2021 Sep; 12(6):1451-1461. PubMed ID: 34527421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.
    Harris VK; Sadiq SA
    Mol Diagn Ther; 2009; 13(4):225-44. PubMed ID: 19712003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating multi-omics biomarkers and postprandial metabolism to develop personalized treatment for anorexia nervosa.
    Shih PB
    Prostaglandins Other Lipid Mediat; 2017 Sep; 132():69-76. PubMed ID: 28232135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Data integration and systems biology approaches for biomarker discovery: challenges and opportunities for multiple sclerosis.
    Villoslada P; Baranzini S
    J Neuroimmunol; 2012 Jul; 248(1-2):58-65. PubMed ID: 22281286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke.
    Montaner J; Ramiro L; Simats A; Tiedt S; Makris K; Jickling GC; Debette S; Sanchez JC; Bustamante A
    Nat Rev Neurol; 2020 May; 16(5):247-264. PubMed ID: 32322099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum proteomics in multiple sclerosis disease progression.
    Tremlett H; Dai DL; Hollander Z; Kapanen A; Aziz T; Wilson-McManus JE; Tebbutt SJ; Borchers CH; Oger J; Cohen Freue GV
    J Proteomics; 2015 Apr; 118():2-11. PubMed ID: 25753122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary and Plasma Metabolomics Identify the Distinct Metabolic Profile of Disease State in Chronic Mouse Model of Multiple Sclerosis.
    Singh J; Cerghet M; Poisson LM; Datta I; Labuzek K; Suhail H; Rattan R; Giri S
    J Neuroimmune Pharmacol; 2019 Jun; 14(2):241-250. PubMed ID: 30315511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal injury in neonates: use of "omics" for developing precision medicine in neonatology.
    Joshi MS; Montgomery KA; Giannone PJ; Bauer JA; Hanna MH
    Pediatr Res; 2017 Jan; 81(1-2):271-276. PubMed ID: 27723726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroproteomics and microRNAs studies in multiple sclerosis: transforming research and clinical knowledge in biomarker research.
    Fawaz CN; Makki IS; Kazan JM; Gebara NY; Andary FS; Itani MM; El-Sayyed M; Zeidan A; Quartarone A; Darwish H; Mondello S
    Expert Rev Proteomics; 2015; 12(6):637-50. PubMed ID: 26479122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Omics biomarkers and early diagnostics].
    Moshkovskii SA
    Biomed Khim; 2017 Oct; 63(5):369-372. PubMed ID: 29080866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomics, proteomics, metabolomics: what is in a word for multiple sclerosis?
    Ibrahim SM; Gold R
    Curr Opin Neurol; 2005 Jun; 18(3):231-5. PubMed ID: 15891405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring Computational Data Amplification and Imputation for the Discovery of Type 1 Diabetes (T1D) Biomarkers from Limited Human Datasets.
    Alcazar O; Ogihara M; Ren G; Buchwald P; Abdulreda MH
    Biomolecules; 2022 Oct; 12(10):. PubMed ID: 36291653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An overview of technologies for MS-based proteomics-centric multi-omics.
    Rajczewski AT; Jagtap PD; Griffin TJ
    Expert Rev Proteomics; 2022 Mar; 19(3):165-181. PubMed ID: 35466851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.